Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(161 products)
- Bcr-Abl(116 products)
- EGFR(595 products)
- FAK(72 products)
- FLT(90 products)
- Fibroblast Growth Factor Receptor (FGFR)(183 products)
- JAK(247 products)
- PDGFR(126 products)
- RAAS(90 products)
- Src(81 products)
- Syk(37 products)
- Thrombin(53 products)
- VDA(2 products)
- VEGFR(246 products)
Show 6 more subcategories
Found 2141 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-32
CAS:EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)Formula:C31H34N6O3Color and Shape:SolidMolecular weight:538.64TCJL37
CAS:TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.Formula:C17H11ClF2N4O2Color and Shape:SolidMolecular weight:376.74CT-721
CAS:CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.Formula:C30H29ClN6OPurity:98%Color and Shape:SolidMolecular weight:525.04VEGFR-2-IN-37
CAS:VEGFR-2-IN-37 (compound 12), a VEGFR-2 inhibitor, exhibits an inhibition rate of approximately 56.9 μM at a concentration of 200 μM.Formula:C18H16N2O2SPurity:98%Color and Shape:SolidMolecular weight:324.4Upadacitinib tartrate
CAS:Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.Formula:C21H33F3N6O11Purity:98%Color and Shape:SolidMolecular weight:602.521TL02-59
CAS:TL02-59: Fgr inhibitor (IC50=0.03nM), also targets Lyn (0.1nM), Hck (160nM), halts acute myelogenous leukemia growth.Formula:C32H34F3N5O4Purity:98.77%Color and Shape:SolidMolecular weight:609.64NMS-P953
CAS:NMS-P953: JAK2 inhibitor, reduces tumor growth in SET-2 model, confirmed in vivo action, good pharmacokinetics and safety.Formula:C16H11ClF3N5OColor and Shape:SolidMolecular weight:381.74Rocbrutinib
CAS:Rocbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits antineoplastic properties [1].Formula:C42H51N9O5Color and Shape:SolidMolecular weight:761.91BEBT-109
CAS:BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.Formula:C27H32N8O3Purity:97.26%Color and Shape:SolidMolecular weight:516.6EGFR-IN-30
CAS:EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.Formula:C28H33BrN7O2PColor and Shape:SolidMolecular weight:610.49UNC4203
CAS:UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.Formula:C30H44N6OColor and Shape:SolidMolecular weight:504.71PonatiLink-1-24
CAS:Ponatinib, also known as PonatiLink-1-24, is a selective inhibitor of the Abelson murine leukemia (ABL) enzyme [1].Formula:C101H144ClF5N12O29Color and Shape:SolidMolecular weight:2120.73BMS-599626 Hydrochloride
CAS:BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.Formula:C27H28ClFN8O3Purity:99.98%Color and Shape:SolidMolecular weight:567.01FGFR-IN-8
CAS:FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.Formula:C27H31Cl2N9O2Color and Shape:SolidMolecular weight:584.5ALK/EGFR-IN-2
CAS:ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12VEGFR-2-IN-9
CAS:VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.Formula:C23H25N3O3Purity:97.19%Color and Shape:SolidMolecular weight:391.46PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Formula:C19H22ClN7O3Purity:98%Color and Shape:SolidMolecular weight:431.88Lepzacitinib
CAS:Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.Formula:C18H21N5O3Purity:99.85%Color and Shape:SolidMolecular weight:355.39EGFR/CSC-IN-1
CAS:EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potentialFormula:C54H54Cl2FN7O7S2Purity:98%Color and Shape:SolidMolecular weight:1067.08EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purity:98.64%Color and Shape:SolidMolecular weight:499.61
